KCC1 Activation protects Mice from the Development of Experimental Cerebral Malaria

Elinor Hortle1, Lora Starrs1, Fiona C. Brown2, Stephen M. Jane2,3,4, David J. Curtis2,3, Brendan J. McMorran1, Simon J. Foote1 & Gaetan Burgio1

Plasmodium falciparum malaria causes half a million deaths per year, with up to 9% of this mortality caused by cerebral malaria (CM). One of the major processes contributing to the development of CM is an excess of host inflammatory cytokines. Recently K+ signaling has emerged as an important mediator of the inflammatory response to infection; we therefore investigated whether mice carrying an ENU induced activation of the electroneutral K+ channel KCC1 had an altered response to Plasmodium berghei. Here we show that Kcc1M935K/M935K mice are protected from the development of experimental cerebral malaria, and that this protection is associated with an increased CD4+ and TNFα response. This is the first description of a K+ channel affecting the development of experimental cerebral malaria.

Plasmodium falciparum malaria is a major cause of mortality worldwide, causing an estimated 219 millions cases and 435,000 deaths in 2018. One of the most severe and lethal complications of P. falciparum infection is the sudden onset of seizures and/or coma, known as cerebral malaria (CM). Its occurrence varies from region to region, with a case fatality rate as high as 9% of severe malaria cases in some areas. The causes of CM are not well understood, but hypotheses include the accumulation of parasitized red blood cells in the brain microvasculature, as well as imbalance in the pro- and anti-inflammatory responses to infection.

In recent years, potassium (K+) signaling has emerged as an important mediator of the immune response to infection. Several studies have shown in vitro that functional outwardly rectifying K+ channels are necessary for macrophage activation and production of TNFα, for activation of the NALP inflammasome, for the activation of T helper cells, and the formation of T regulatory cells. The K+ content of the RBC also has a large effect on intra-erythrocytic Plasmodium. It has been shown that an outwardly directed K+ gradient is needed for normal parasite growth and maintenance of the parasite plasma membrane potential. A mouse line expressing an activated form of K-Cl co-transporter type 1 (KCC1), discovered from a large scale N-ethyl-N-nitrosourea (ENU) mutagenesis screen in mice, has recently been described. The induced mutation – an M to K substitution at amino acid 935 of the protein – impairs phosphorylation of neighboring regulatory threonines, leading to over-activation of the transporter. The resulting increase in K+ efflux from the RBC causes Kcc1M935K mice to display microcytic anemia, with homozygous mutants showing a 21% decrease in Mean Corpuscular Volume (MCV), 8% decrease in total hemoglobin, and 21% increase in number of red cells. Mutant cells are also significantly less osmotically fragile, indicating a dehydration of the red blood cells.

Here we use the Kcc1M935K mouse line to investigate the effect of increased host K+ efflux on susceptibility to malaria infection. When Kcc1M935K mice were infected with Plasmodium berghei, they showed protection from the development of experimental cerebral malaria (ECM), associated with a significant increase in CD4+ T cells and TNFα in the brain during infection, suggesting K+ efflux through KCC1 alters the inflammatory response to infection. This is the first description of a cation co-transporter affecting the development of ECM in mice.

1Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Australian Capital Territory, Australia. 2Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Australia. 3The Alfred Hospital, Melbourne, Australia. 4Department of Medicine, Central Clinical School, Monash University, Melbourne, Australia. Correspondence and requests for materials should be addressed to G.B. (email: Gaetan.burgio@anu.edu.au)
**Results**

**Kcc1<sup>M935K</sup>** mice are protected against *P. berghei* infection. *Kcc1<sup>M935K/M935K</sup>* mice were inoculated with *P. berghei* to determine their resistance to parasitic infection. Cumulative survival and peripheral parasitemia were monitored daily over the course of infection. When mice were infected with 1 × 10<sup>7</sup> *P. berghei* parasitized red cells, survival was significantly increased in the mutants, with 100% of homozygotes surviving past day 10 of infection, compared to 7% of WT females (P = 0.0004; Fig. 1A), and 11% of WT males (P < 0.0001; Fig. 1C) respectively. Significantly lower parasitemia was observed in both *Kcc1<sup>M935K</sup>* females and males. In females, parasitemia was reduced by 63% on day 7, 48% on day 8, and 42% compared to WT, on day 9 post inoculation. Parasitemia in males was similarly reduced, by 66%, 41%, and 53% respectively (Fig. 1A–D).

To determine if this reduction in parasitemia was caused by impairment in the parasite's ability to invade *Kcc1<sup>M935K/M935K</sup>* RBCs and survive within them, we conducted TUNEL staining of infected RBCs to detect fragmented nuclei in the parasites indicative of maturation arrest<sup>15</sup>, and an *in vivo* invasion and maturation assay as previously described<sup>16</sup>. No significant differences were observed in the TUNEL assay (Fig. 1E) but a significant 2-folds increase in parasitic growth for *Kcc1<sup>M935K/M935K</sup>* RBCs at 13 hours (P < 0.001) and 21 hours (P < 0.001) (Fig. 1F), suggesting the *Kcc1<sup>M935K</sup>* mutation does not affect parasite invasion but promotes intra-erythrocytic survival. We therefore hypothesized parasitic clearance is impaired to explain this increase in growth coupled with the lower parasitemia for *Kcc1<sup>M935K/M935K</sup>* RBCs. To address this postulate, during the invasion and growth assay above (Fig. 1F), we also measured the proportion of labeled RBCs for WT and *Kcc1<sup>M935K/M935K</sup>* RBCs across time from 30 minutes to 24 hours post inoculation and found no difference in remaining *Kcc1<sup>M935K/M935K</sup>* labeled RBCs to WT (Fig. 1G), indicative of no increase in parasitic systemic clearance and/or sequestration for *Kcc1<sup>M935K/M935K</sup>* RBCs.

In the experiments described above, 90% WT mice succumbed between days 8 and 10 post infection (Fig. 1A–D). Death at this point in *P. berghei* infection is usually caused by experimental cerebral malaria (ECM), and unrelated to the level of peripheral parasitemia. Combined with our results from the TUNEL and invasion assays, this hinted that the *Kcc1<sup>M935K</sup>* mutation may not affect parasite growth, but may rather provide more systemic protection from ECM. To confirm that the survival phenotype of *Kcc1<sup>M935K/M935K</sup>* was not caused by its significantly lower parasitaemia, mice were infected with a high dose of *P. berghei* at 1 × 10<sup>7</sup> parasitised red cells. Under these conditions mutants showed a similar increase in survival despite showing higher peripheral parasitemia than those at which WT mice began to die in low dose experiments (Figure S1A,B), suggesting increased survival is not caused by low parasitaemia. We also infected mice with a dose of 1 × 10<sup>5</sup> *P. berghei* iRBC at which 50% of WT mice survived beyond day 10 of infection. In this experiment *Kcc1<sup>M935K/M935K</sup>* had no difference in survival and no significant differences in parasitemia (Fig. 1H–I). This suggests that parasite invasion or maturation is unlikely to be defective in *Kcc1<sup>M935K</sup>* mutant mice.

**Kcc1<sup>M935K</sup>** promotes resistance to ECM. When infected with *P. berghei* in the experiments described above, most WT mice died 8 to 10 days after infection. To determine if the WT mice were succumbing to *P. berghei* infection in our challenges as a result of ECM, mice were infected with *P. berghei* and symptoms of ECM were scored according to severity, from 0 (no symptoms) to 5 (death). Severe clinical symptoms were observed in WT mice, with most dying from seizures, whereas *Kcc1<sup>M935K/M935K</sup>* remained asymptomatic for the length of the experiment (Fig. 2A). One of the key hallmarks of cerebral malaria is breakdown of the blood brain barrier. Therefore, mice were injected intravenously with Evan’s Blue to assess blood brain barrier integrity. Infection WT mice showed an average of 14.5 ± 2.9 grams of dye per gram of brain tissue, which was higher than the 8.1 ± 1.4 g/g observed in uninfected mice. Infected *Kcc1<sup>M935K/M935K</sup>* more closely resembled uninfected mice, with 9.4 ± 1.3 g/g (Fig. 2B,C). Although none of these differences was significant, the clear trend to higher staining in mutant mice compared to WT, suggested the extent of damage in *Kcc1<sup>M935K/M935K</sup>* was not sufficient to lead to ECM death. ECM is also associated with increased sequestration of infected RBCs in the microvasculature. We therefore assayed the relative amount of parasite sequestration in the brain and spleen by PCR of *P. berghei* 18S RNA. *Kcc1<sup>M935K/M935K</sup>* showed a trend to decreased parasitemia in the brain, and increased parasitemia in the spleen (Fig. 2D) indicating increased splenic sequestration, possibly due to reduced ability for the parasite to cross the blood brain barrier. This trend was confirmed by measuring infected RBCs (iRBCs) in the brain by flow cytometry (Fig. 2E). To further assess the postulate of reduced sequestration of the parasitized RBCs in the brain tissue, we histologically assessed the presence of residual focal hemorrhages, oedema and neuropil changes in the brain tissue. At the pathological examination, the brain tissue appears normal for *Kcc1<sup>M935K/M935K</sup>* or WT mice (Fig. 3A–C), with no presence of residual hemorrhages, petechies or oedema, and no difference between uninfected or infected *Kcc1<sup>M935K/M935K</sup>* and WT in either the leukocytic population (Figure S3A) or iRBC (Figure S3B) population in the brain. However, we found the presence of hemozoin pigmentaion with significant disruption of the neuropil accompanied with white blood cell and uninfected RBC infiltrates in the infected WT mice at day 10 post inoculation (Fig. 3B), whereas this was not observed for infected *Kcc1<sup>M935K/M935K</sup>* mice (Fig. 3D).

Interestingly, pathological examination of the spleen indicates no architectural differences between infected and uninfected *Kcc1<sup>M935K/M935K</sup>* and WT mice (Figure S2), and no change in the percentage of white pulp present in the spleens of uninfected or infected *Kcc1<sup>M935K/M935K</sup>* and WT (S2C), but the presence of hemozoin pigmentation in both strains indicates splenic sequestration, though it appears that infected WT have a slight increase compared to all other treatments (Figure S2C,D, S3B) though this is not significant. There is also an observable hyperproliferation of white blood cells in infected *Kcc1<sup>M935K/M935K</sup>* mice (Figure S2D), which was not evident in the spleen of infected WT mice (Figure S2C), though these differences were not significant. Together with the clinical scores and Evan’s blue staining, this suggests that WT mice are more likely to succumb from ECM due to a breakdown of the blood brain barrier and a moderate increase in iRBC population in the brain compared with *Kcc1<sup>M935K/M935K</sup>* which are more likely to be resistant to the development of this condition, possibly through an...
Figure 1. The Kcc1M935K mutation causes resistance to *P. berghei*. (A,B) Cumulative survival and average ± SEM parasitemia for WT and Kcc1M935K/M935K in male mice. WT n = 28, WT Kcc1M935K/M935K n = 14. Combined results of two independent experiments. (C,D) Cumulative survival and average ± SEM parasitemia for WT and Kcc1M935K/M935K in female mice. WT n = 8, Kcc1M935K/M935K n = 10. Combined results of two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. P values calculated using Log rank test or the student’s T-test. (E) Average ± SEM percentage of parasites which are TUNEL positive. (F and G) Average ± SEM fold change in parasitemia and percentage of remaining Kcc1M935K/M935K labelled cells compared to WT labelled cells injected into the same *P. berghei* infected host (n = 8) from 30 minutes to 21 hours post inoculation. (H and I) Cumulative survival and average ± SEM parasitemia for WT and Kcc1M935K/M935K in female mice in challenge where WT did not develop CM. WT n = 7, Kcc1M935K/M935K n = 5.
Figure 2. The Kcc1<sup>M935K</sup> mutation causes resistance to cerebral malaria. (A) Clinical score for WT (n = 37) and Kcc1<sup>M935K/M935K</sup> (n = 24) mice infected with <i>P. berghei</i> 0 = no symptoms, 1 = reduced movement, 2 = rapid breathing/hunched posture, 3 = ruffled fur/external bleeding, 4 = fitting/coma, 5 = death. (B) Amount of Evan's Blue dye extracted from <i>P. berghei</i> infected Kcc1<sup>M935K/M935K</sup> (n = 8), WT (n = 7) and uninfected (n = 4) brains. (C) Representative brains dissected from mice injected with Evan's Blue dye. (D) Relative amount of <i>P. berghei</i> 18 s RNA normalized to mouse GAPDH in brain, spleen, and blood of infected Kcc1<sup>M935K/M935K</sup> (n = 4), WT (n = 4). (E) Relative proportion of <i>P. berghei</i> infected Red Blood Cells in the brain from flow cytometry analysis. The population was gated on TER119 and Hoescht 33352 positivity. A comparison of the infected RBC (iRBC) in the brain of female WT and Kcc1<sup>M935K/M935K</sup> mice, as an average percentage of total RBC in the brain ± SEM. Uninfected controls show low background staining as quantified using FACS. Uninfected WT and Kcc1<sup>M935K/M935K</sup> n = 3. Infected WT and Kcc1<sup>M935K/M935K</sup> n = 4. Values are average ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. P values calculated using multiple T test with Two-stage linear step-up procedure of Benjamin, Krieger ad Yekutieli with Q = 1% (A), or ordinary one-way ANOVA (B).
increased sequestration of parasites in the spleen, which also aids in preventing iRBC localization to the blood brain barrier.

**Kcc1<sup>M935K</sup> display an abnormal immune response to infection.** It has been shown that depletion of CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, and inflammatory monocytes can prevent the development of ECM<sup>17–19</sup>. ECM resistance is also observed in mice with impaired thymic development of CD8<sup>+</sup> T cells<sup>20</sup>. Since the parasites were present in the brain, and KCC1 is expressed ubiquitously<sup>21</sup>, we postulated that the Kcc1<sup>M935K</sup> mutation might cause alterations to some of these immune cell populations in the brain resulting in a stimulation of the immune response and impairment of parasite growth or increase clearance of the parasites. Therefore, the relative amounts of CD4<sup>+</sup> and CD8<sup>+</sup> T cells were measured by flow cytometry in the brain, blood, spleen, and thymus, both in uninfected mice, and before the mice succumbed to ECM, where the inflammatory response is expected to be highest<sup>22,23</sup>. Consistent with the hypothesis that KCC1<sup>M935K/M935K</sup> mice are resistant to ECM, differences in CD4<sup>+</sup> and CD8<sup>+</sup> T cells were observed in the brain (Fig. 4A,B), but not in the blood, spleen, or thymus (Fig. 4C,D and S4). When uninfected, KCC1<sup>M935K/M935K</sup> showed a 4-fold increase in the average number of CD4<sup>+</sup> T cells in the brain compared to WT (Fig. 3A). During infection, KCC1<sup>M935K/M935K</sup> had a slight increase in the average amount of CD4<sup>+</sup> T cells in the brain compared to WT (Fig. 4C). Importantly, KCC1<sup>M935K/M935K</sup> showed a significant 2.5-fold decrease in CD8<sup>+</sup> T cells in the brain compared with infected WT (p = 0.028). There were no significant changes in CD8<sup>+</sup> T cells in either genotype from their baseline when placed under infection in the brain (Fig. 4B) or in the blood (Fig. 4D).

Together these results suggest that both at baseline, and prior to the accumulation of CD4<sup>+</sup> and CD8<sup>+</sup> in the brain of infected WT mice, KCC1<sup>M935K/M935K</sup> have an abnormal T cell response.

One of the major host processes known to contribute to the development of cerebral malaria in *P. berghei* infection is an over-active inflammatory response. Both *in vivo* neutralisation of host molecules, and studies with knock-out mice have shown that cerebral malaria can be prevented by depletion of the pro-inflammatory cytokines IFN-γ<sup>24,25</sup> and TNFα<sup>26</sup>, and can be induced by depletion of the anti-inflammatory cytokine IL-10<sup>27</sup>. ECM resistance is also observed in mice with defective T cell dependent IFN-γ production<sup>28</sup>. We therefore measured cytokine levels in infected mice in two ways: by ELISA in the brain and blood at a single time-point when

---

The Kcc1<sup>M935K</sup> mutation protects the brain against parasitized RBCs. H&E stained brain sections from representative (A) uninfected WT, (B) infected WT, (C) uninfected Kcc1<sup>M935K/M935K</sup>, and (D) infected Kcc1<sup>M935K/M935K</sup> mice. The orange arrow indicates the presence of hemozoin pigmentation within the RBCs. Sections are 20x magnification, insets are 1.25x magnification.
all the WT mice succumbed to ECM, so all mice were sacrificed; and by CBA array in the plasma at several
time-points over the first 10 days of infection.

It was noted that uninfected Kcc1 M935K/M935K mice showed a higher basal TNF-α and IL-1β level than WT,
however, this difference was not significant. At the single time-point, infected Kcc1M935K/M935K showed a signifi-
cant 1.7-fold increase in the average TNF-α concentration in the brain (5723 pg/ml compared to 3329 pg/ml) and
blood (2503 pg/ml compared to 1504 pg/ml) with a respective p-value of 0.0068 in the brain and 0.0134 in the
blood (Fig. 5A), as well as a trend to increased IL-1β in the brain (Fig. 5B). There were no differences in IFN-γ
in either the brain or blood at this time-point (Fig. 5C). By CBA array, Kcc1M935K/M935K showed no difference in
plasma cytokine levels early in infection; however, a 60% reduction in the amount of IFN-γ, and a 75% reduc-
tion in IL-6 were observed on day 9 of infection (391 pg/ml compared to 969 pg/ml, and 2.4 pg/ml compared to
10.3 pg/ml respectively). This was followed by an 85% reduction in the amount of IL-10 on day 10 of infection (an
average of 8 pg/ml in Kcc1M935K compared to 55 pg/ml in WT) (Fig. 5). A slight increase in the amount of TNF-α
(P = 0.040) was also observed on day 7 (Figure S5). Together this indicates a possible protective effect of the
Kcc1M935K/M935K mice against ECM by altering the balance of IFN-γ and TNF-α responses to infection.

Discussion

This study provides the first evidence that host KCC1 plays a role in malaria resistance. It shows that
over-activation of the transporter is likely to provide protection to experimental cerebral malaria (ECM) in P.
berghei infection. This is the first description of a mutation in a cation transporter that has an effect on ECM;
other previously discovered genes have directly involved host cytokines, antigen presentation28,29, or erythrocyte
membrane proteins30–32.

Despite the fact that Kcc1 M935K/M935K showed significantly lower parasitemia than WT during the first 10 days
of infection, the mutation did not appear to have a cell autonomous effect on parasite invasion and survival within
the RBC. One possible explanation for this observation is suggested by the fact that P. berghei infected RBCs have
the ability to cytoadhere to the endothelium of blood vessels. Lower levels of sequestration in the mutants would
leave more late stage parasites vulnerable to splenic clearance, and therefore result in reduced parasite burden. Reduced sequestration would also be consistent with protection from cerebral malaria, as infected cells would be less likely to adhere within the microvasculature of the brain. Our results from P. berghei 18S rRNA and histology examination support this hypothesis, showing trends to reduced parasite burden in the brain and increased burden in the spleen but these are not significant due to the genetic variation amongst mice.

Our results show increased CD4+ and decreased CD8+ T cells in the brains of infected KCC1 M935K/M935K compared with infected WT mice. This corroborates previous reports showing CD8+ are the major mediators of ECM. Surprisingly, in these experiments we did not see the expected increases in CD4+ and CD8+ T cell populations in the brain of WT mice during infection. This may indicate that we assayed the mice before the WTs had mounted a substantial immune response to infection. The fact that KCC1M935K/M935K did show an increase in CD4+ during infection, even at this early time-point, suggests that the mutant mice are able to respond more quickly than WT to infection, although it remains unclear from these experiments why mutants would have altered T cell populations in the brain even when uninfected. KCC1 is expressed on a wide range of immune cells, and may greatly affect their function. Previous studies have shown that K+ efflux can alter cellular cytokine production, can increase assembly of the NALP inflammasome in response to pathogen associated proteins, and is essential for macrophage migration. All of these may contribute to both T cell migration, and the increased IL-1β and TNF-α observed in KCC1M935K mice.

The increase of pro-inflammatory cytokines in the brains of KCC1 M935K mice was surprising, as increased TNF-α have previously been associated with more severe CM (reviewed in 35,36). However, it has been shown that neither TNF-α knock-out, or neutralization with antibodies, is sufficient to prevent CM37,38, suggesting that the soluble cytokine is not itself causative of the condition. Although we did not find any significant differences in IFN-γ in the brains of KCC1 M935K mice at our single time point, we did observe a significant reduction in the plasma two days later than the significant increase in TNF-α. Interestingly, both IFN-γ knock-out and neutralization with antibodies, does protect against ECM (reviewed in 39). It may therefore be that the KCC1 M935K mutation does not protect by modulation of any one cytokine, but by a better ability to quickly reduce inflammation after its initial peak.

Here we have shown that activation of KCC1 is likely to provide protection to P. berghei by preventing the development of experimental cerebral malaria (ECM). This is the first description of a mutation in a transporter

---

**Figure 5.** The Kcc1 M935K mutation increases pro-inflammatory cytokines in the brain. Average ± SEM amount of (A) TNF-α (B) IL-1β (C) IFN-γ in uninfected WT and Kcc1 M935K/M935K (n = 3), and P. berghei infected WT and Kcc1 M935K/M935K (n = 4). *P < 0.05, **P < 0.01 P values calculated using student’s T-test.
that has an effect on ECM. Previous studies have shown that pharmacological activation of KCC channels is achievable\cite{40,41}, therefore future research into KCC1 activation may provide novel treatments for cerebral malaria.

**Methods**

**Animals.** Mice were bred under specific pathogen free conditions. All procedures conformed to the National Health and Medical Research Council (NHMRC) code of practice. All mouse procedures have been approved by the Australian National University Animal Experimentation Ethics Committee (AEEC A2014/054). The Kcc1<sup>M935K</sup> mutation is carried on a mixed BALB/c and C57BL/6 background\cite{44}. These two mouse strains differ in their susceptibility to *P. berghei*, and this introduced a greater amount of variability into results than is usually observed. Therefore, WT × WT and Kcc1<sup>M935K/M935K</sup> × Kcc1<sup>M935K/M935K</sup> breeding pairs were maintained. To exclude the possibility that the resistance phenotype was due to the mixed background, and carried by chance in mutant breeding pairs, Kcc1<sup>M935K</sup> was periodically crossed back to WT, and new WT × WT and Kcc1<sup>M935K/M935K</sup> × Kcc1<sup>M935K/M935K</sup> pairs established from the progeny.

**Infections.** Experiments used the rodent parasite *P. berghei* ANKA (clone 15Cy1, donation from Prof Tania de Koning-Ward, Deakin University, Australia). Parasite stocks were prepared from passage through SJL/J mice, susceptible to *P. berghei* infection but don’t develop ECM, as described previously\cite{42}. Experimental mice were infected intraperitoneally at a dose of 1 × 10<sup>6</sup> or 1 × 10<sup>5</sup> parasitised RBC per mouse. Blood stage parasitemia was determined by counting thin smears from tail blood stained in 10% Giemsa solution. A least 300 total RBCs were counted per slide.

**Histology.** Uninfected, *P. berghei* infected mice and control are humanely euthanized. The brain was transcardially perfused by with 10 ml of 0.1 M ice cold phosphate buffered saline solution (PBS) followed by 10 ml of ice cold 4% paraformaldehyde (PFA) and fixed into 70% ethanol. Brains and spleens from 5 mice from each group were serially sectioned and stained with Hematoxylin and Eosin (H&E). Brain and spleen sections were independently examined by 2 different pathologists. Number of hemorrhages, leukocytes, infected red blood cells were manually determined at a magnification x20. 10 fields of view were counted for each slide.

Thin tail smears from *P. berghei* infected mice were fixed in 100% MeOH, and stained with an APO-BrdU TUNEL assay kit according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA). Slides were examined on an upright epifluorescence microscope (ZIESS) 600x magnification. 10 fields of view were counted for each slide.

**Evans Blue.** *P. berghei* infected mice, and uninfected controls, were injected via IV with 200μl 1% Evans Blue/PBS solution. 1 hr post injection, mice were sacrificed and their brains collected and weighed. Brains were placed in 2 ml 10% neutral buffered formalin at room temperature for 48hrs to extract dye. 200μl PBS solution. 1 hr post injection, mice were sacrificed and their brains collected and weighed. Brains were placed in 2 ml 10% neutral buffered formalin at room temperature for 48hrs to extract dye. 200μl of formalin from each brain was then collected and absorbance measured at 620 nm. Amount of Evans blue extracted per gram brain tissue was calculated using a standard curve ranging from 40μg/ml to 0μg/ml. Injections were carried out on the day of infection that the first mouse died.

**Clinical Score.** Mice were monitored three times daily, and given a score from 0 to 5 based on the type and severity of their symptoms. ‘0’ indicated no symptoms; ‘1’ reduced or languid movement; ‘2’ rapid breathing and/or hunched posture; ‘3’ ruffled fur, dehydration and/or blood in urine; ‘4’ fitting and/or coma; ‘5’ death. Mice were considered comatose if they were unable to right themselves after being placed on their side. The highest score recorded for each mouse on each day was used to generate daily averages.

**Cytokines.** Peripheral blood was taken either by cardiac puncture or mandibular bleed in a microcentrifuge tube coated with anticoagulants and centrifuged for 4 minutes at 11,000 × g. Plasma was then taken into a separate tube and stored at −20 °C until needed. Cytokine analysis was conducted on un-diluted plasma using a CBA Mouse Th1/Th2/Th17 Cytokine Kit to the maker’s instructions (BD biosciences).

**Lymphocyte and Infected Red Blood Cell Analysis.** Peripheral blood was taken either by cardiac puncture or mandibular bleed, and lymphocytes were isolated on Ficoll-Paque™ according to the maker’s instructions. Lymphocytes were then incubated with Fc-block in MT-FACS for 10 minutes at 4 °C.

Both spleen and thymus were prepared for flow cytometry using the same method. ½ of each organ was passed through a 70μm BD Falcon Cell Strainer with 0.5 ml of MT-FACS buffer, and then centrifuged at 300 × g for 5 minutes at 4 °C. The supernatant was removed and the pellet re-suspended in 5 ml cold MT-FACS buffer. A 200μl aliquot of this suspension was then incubated with 0.8μl Fc-block.

Blood, spleen and thymus samples were then stained with CD4-PacificBlue, CD11-PE, CD8-FITC, and CD3-APC-Cy7. Samples were acquired using a BD FACSAria™ II flow cytometer, and analysed using BD FACSDiva™ software (BD Biosciences).

For comparative analysis of CD3+CD4+ and CD3+CD8+ brain lymphocyte populations using flow cytometry, the brains of WT and mutant mice were harvested when WT mice succumbed to ECM. Briefly, the entire brain was passed through a 70μm BD Falcon Cell Strainer and collected post-straining in 1.5 ml of PBS and then centrifuged at 500 × g for 5 minutes at 4 °C. The supernatant from this was used for ELISA (methods below). The cell pellet was then toppped up to a total volume of 400 μl with PBS, and split as 300 μl for FACS staining, and 100 μl for PCR (methods below). The samples were passed through a 70μm BD Falcon Cell Strainer again and then centrifuged at 1500 × g for 5 minutes at 4 °C, prior to washing once with PBS; 10 μl of this pellet was then removed for infected RBC (iRBC) analysis. The remaining 40 μl cell pellet was blocked with 5 μl Fc block for 10 minutes at 4 °C. The pellet was then washed twice with 200 μl MTRC, and incubated with CD3-BV605, CD8-FITC and CD4-APC.
antibodies. Samples were acquired at 2.5 × 10⁶ cells per sample, using a BD LSRFortress™, and analysed using BD FlowJo™ software.

The brain cell pellet previously removed for iRBC analysis, was incubated with TER-119-PE-Cy7 antibody, with Hoescht 33342, and JC-1 dyes in MTRC, and 2.5 × 10⁷ cells were acquired per sample using a BD LSRFortress™, and analyzed using BD FlowJo™ software.

18S PCR from Brain, Spleen and Blood. Brain samples were processed as described above. The spleen was also passed through a 70 µm BD Falcon Cell Strainer and resuspended to a total volume of 1.5 ml in PBS.

These cells were then centrifuged at 1500 × g for 2 minutes at 4 ℃, and the supernatant was collected for ELISA (methods below). The pellet was resuspended to a total of 800 µl and split in two, with 400 µl taken for PCR, and 400 µl snap frozen. Peripheral blood was collected using a cardiac puncture, and centrifuged at 1500 × g 10 minutes at 4 ℃. The supernatant was taken for ELISA (below) and the pellet was lysed using two volumes of 0.15% saponin in PBS for 30 minutes at 37 ℃. Brain and spleen samples were processed similarly in order to successfully lyse any iRBC. The samples were then centrifuged at 10 000 × g for 10 minutes at 4 ℃, and the pellet was washed three times with ice cold PBS. Following this, all samples were processed using the Qiagen DNeasy Blood and Tissue kit following the manufacturer’s instructions. The quality and yield of DNA was quantified using a NanoDrop spectrophotometer. 200 ng of each sample was set up in a PCR reaction with 1x MyTaq™ Mix and 0.4 µM of GAPDH primers (Forward: GATGCCCTCCATGTGGT; Reverse: TGGGAGTTGCTGTTGAAG), or 0.4 µM of 18s primers (Forward: CAGACCTGTTGCTGCCTTAAAC; Reverse: GCTTGGGCCTTAATTTGACTC). The reaction parameters for GAPDH were as follows, 95 ℃ for 5 minutes before 35 cycles of 95 ℃ 30 seconds, 50 ℃ 30 seconds, 72 ℃ 1 minute, and a final extension at 72 ℃ 2 minutes. Since the genome of P. berghei is AT rich, the PCR protocol for 18s was 95 ℃ 5 minutes, before 35 cycles of 95 ℃ for 30 seconds, 50 ℃ for 1 minute, 68 ℃ for 2 minutes, and a final extension of 68 ℃ for 5 minutes. These reactions were then electrophoresed on a 1% agarose gel, and imaged using a Bio-Rad Gel Doc™ XR+ Gel Documentation System. Densiometry analysis was conducted on this bands using Image J software, and standardized to GAPDH densitometry analysis.

ELISA from brain and blood. Samples were processed as described above, with the supernatants removed and saved for ELISA. ELISAs were conducted following the manufacturers’ protocols, with the IL-1β and IFN-γ (ELISAKIT.com, EK-0033 and EK-0002, respectively) and TNF-α and IFN-γ (ThermoFisher Scientific KMC4022). Samples were diluted 1 in 5 and 1 in 10 for IL-1β; 1 in 4 and 1 in 8 for IFN-γ, and 1 in 10 and 1 in 20 for TNF-α. The data was collected using a Tecan M200 plate reader.

In-vivo Invasion Assay. Blood from Mutant and WT uninfected mice was collected by cardiac puncture. 1800 µl of blood was collected and pooled for each genotype, then halved and stained with either NHS-Atto 633 (1 µl/100 µl) or sulfobiotin-LC-NHS-Biotin (1 µl/100 µl of 25 mg/ml in DMF). Cells were then incubated at RT for 30 minutes and washed twice in MT-PBS. Stained cells were combined in proportions to achieve the following combinations:

WT-Biotin + Mutant-Atto 2) WT-Atto + Mutant Biotin. Combined cells were then resuspended in 2 ml MT-PBS, and injected intravenously into 4 WT P. berghei infected mice at 1–5% parasitemia, plus 1 uninfected control, were injected with 200 µl dye combination 1; the same numbers of mice were injected with 200 µl dye combination 2. Injections were carried out when parasites were undergoing schizogeny, at ~1am. 30 minutes post injection, 1 µl tail blood was collected and stained for 30 minutes at 4 ℃ in 50 µl MT-PBS containing 0.25 µl CD45-APC-Cy7, 0.25 µl CD71-PE-Cy5, 0.5 µl Step-PE-Cy7. Next, 400 µl MTPBS containing 0.5 µl Hoechst 33342 and 1 µl 800 µg/ml Thiazole orange was added, and cells were incubated for a further 5 minutes at 4 ℃. Stained cells were then centrifuged at 750 × g for 3 minutes, resuspended in 700 µl MT-PBS, and analyzed on a BD Fortessa Flow Cytometer. 2 × 10⁶ cells were collected for each sample, and data was analysed using FlowJo (FlowJo, LLC, Oregon, USA).

Statistical analysis. P values were determined using Log-rank test, Mann-Whitney U test or ordinary one-way ANOVA where appropriate. Statistics on the clinical score (Fig. 2A) was determined using two-stage linear step-up procedure of Benjamin, Krieger ad Yekutieli with Q = 1%.

References
1. WHO. World Malaria Report. 161 (World Health Organization, 2018).
2. Grau, G. E. & Craig, A. G. Cerebral malaria pathogenesis: revisiting parasite and host contributions. Future microbiology 7, 291–302, https://doi.org/10.2217/fmb.11.155 (2012).
3. Rockett, K. A. et al. Reappraisal of known malaria resistance loci in a large multicenter study. Nat Genet 46, 1197–1204, https://doi.org/10.1038/Ng.3107 (2014).
4. Brooks, H. M. & Hawkes, M. T. Repurposing Pharmaceuticals as Neuroprotective Agents for Cerebral Malaria. Curr Clin Pharmacol https://doi.org/10.2174/1574884712666170704144042 (2017).
5. Qiu, M. R., Campbell, T. J. & Breit, S. N. A potassium ion channel is involved in cytokine production by activated human macrophages. Clin Exp Immunol 130, 67–74 (2002).
6. Ren, J. D. et al. Involvement of a membrane potassium channel in hepatic sulphate-induced activation of macrophages. Immunology 141, 345–352, https://doi.org/10.1111/imn.12193 (2014).
7. Petrilli, V. et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 14, 1583–1589, https://doi.org/10.1038/sj.cdd.4402195 (2007).
8. Bittner, S. et al. Upregulation of K2P5.1 potassium channels in multiple sclerosis. Ann Neurol 68, 58–69, https://doi.org/10.1002/ana.22010 (2010).
9. Fellerhoff-Losch, B. et al. Normal human CD4(+) helper T cells express Kv1.1 voltage-gated K(+) channels, and selective Kv1.1 block in T cells induces by itself robust TNFalpha production and secretion and activation of the NFkappaB non-canonical pathway. *J Neural Transm* (Vienna) **123**, 137–157, https://doi.org/10.1007/s00702-015-1446-9 (2016).

10. Wulff, H. et al. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. *J Clin Invest* **111**, 1703–1713, https://doi.org/10.1172/JCI16921 (2003).

11. Staines, H. M., Ellory, J. C. & Kirk, K. Perturbation of the pump-leak balance for Na(+) and K(+) in malaria-infected erythrocytes. *Am J Physiol Cell Physiol* **280**, C1576–1587 (2001).

12. Brand, V. B. et al. Dependence of Plasmodium falciparum *in vitro* growth on the cation permeability of the human host erythrocyte. *Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology* **13**, 347–356, 75122 (2003).

13. Allen, R. J. & Kirk, K. The membrane potential of the intraerythrocytic malaria parasite Plasmodium falciparum. *J Biol Chem* **279**, 11264–11272, https://doi.org/10.1074/jbc.M311110200 (2004).

14. Brown, F. C. et al. Activation of the erythroid K-Cl cotransporter Kcc1 enhances sickle cell disease pathology in a humanized mouse model. *Blood* **126**, 2863–2870, https://doi.org/10.1182/blood-2014-10-609362 (2015).

15. McMorrin, B. J. et al. Platelets kill intraerythrocytic malarial parasites and mediate survival to infection. *Science* **323**, 797–800, https://doi.org/10.1126/science.1166296 (2009).

16. Lelliott, P. M., McMorrin, B. J., Foote, S. J. & Burgio, G. In vivo assessment of rodent Plasmodium parasitemia and morozone invasion by flow cytometry. *J Vis Exp*, e52736, https://doi.org/10.3791/52736 (2015).

17. Claser, C. et al. CD8+ T cells and IFN-gamma mediate the time-dependent accumulation of infected red blood cells in deep organs during experimental cerebral malaria. *PLoS One* **6**, e18720, https://doi.org/10.1371/journal.pone.0018720 (2011).

18. Hermsen, C., van de Wiel, T., Mommers, E., Sauerwein, R. & Eling, W. Depletion of CD4+ or CD8+ T cells prevents Plasmodium berghei induced cerebral malaria in end-stage disease. *Parasitology* **114**(Pt 1), 7–12 (1997).

19. Schumak, B. et al. Specific depletion of Ly6C(hi) inflammatory monocytes prevents immunopathology in experimental cerebral malaria. *PLoS One* **10**, e0124080, https://doi.org/10.1371/journal.pone.0124080 (2015).

20. Bølgen, S. E. et al. An N-Ethyl-N-Nitrosourea (ENU)-Induced Dominant Negative Mutation in the JAK3 Kinase Protects against Cerebral Malaria. *PLoS One* **7**, e31012, https://doi.org/10.1371/journal.pone.0031012 (2012).

21. Gillen, C. M., Brill, S., Payne, J. A. & Forbush, B. 3rd Molecular cloning and functional expression of the K-Cl cotransporter from *Homo sapiens*. *Biochem Biophys Res Commun* **178**, 137–157, https://doi.org/10.1016/S0006-291X(90)80260-8 (1991).

22. Hanum, P. S., Hayano, M. & Kojima, S. Cytokine and chemokine responses in a cerebral malaria-susceptible or -resistant strain of mice to Plasmodium berghei ANKA infection: early chemokine expression in the brain. *Int Immunol* **15**, 633–640 (2003).

23. Lacerda-Queiroz, N. et al. Inflammatory changes in the central nervous system are associated with behavioral impairment in Plasmodium berghei (strain ANKA) infected mice. *Exp Parasitol* **125**, 271–278, https://doi.org/10.1016/j.exppara.2010.02.002 (2010).

24. Yanez, D. M., Manning, D. D., Cooley, A. J., Weidanz, W. P. & van der Heyde, H. C. Participation of lymphocyte subpopulations in the pathogenesis of experimental murine cerebral malaria. *Am J Physiol Cell Physiol* **280**, C1576–1587 (2001).

25. Koch, O. *J Infect Dis* **175**, 1091–1097 (1996).

26. Simpson, J. A., Aarons, L., Collins, W. E., Jeffery, G. M. & White, N. J. Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. *Parasitology* **124**, 247–263 (2002).

27. Kan, X. H. et al. The membrane potential of the intraerythrocytic malaria parasite *Plasmodium falciparum*. *J Exp Med* **185**, 1664–1665, https://doi.org/10.1084/jem.20061664 (2006).

28. Dunst, J., Kamena, F. & Matuschewsk, K. Cytokines and Chemokines in Cerebral Malaria Pathogenesis. *Expert Opin Ther Targets* **113**, 71–82, https://doi.org/10.1080/14728222.2017.1275569 (2017).

29. Yamada, K. et al. Small-molecule WNK inhibition regulates cardiovascular and renal function. *J Clin Invest* **129*(2)*, 785–796, JCI130660 (2019).

30. Yamasaki, K. et al. Cytotoxic T lymphocytes: accelerated expansion and enhanced IFN-gamma secretion by rodent Plasmodium parasites *in vivo*. *Malar J* **13**, 100, https://doi.org/10.1186/s12936-014-0491-6 (2014).

Acknowledgements

We would like to acknowledge Shelley Lampkin and Australian Phenomics Facility (APF) for the maintenance of the mouse colonies. This study was funded by the National Health and Medical Research Council of Australia (Program Grant 490037, and Project Grants 605524 and APP104790), the National Collaborative Research Infrastructure Strategy (NCRIS), the Education Investment Fund from the Department of Education and Training, the Australian Phenomics Network, Howard Hughes Medical Institute and the Bill and Melinda Gates Foundation. This study utilizes the Australian Phenomics Network Histopathological and Organ Pathology service, University of Melbourne. We finally would like to thank Dr John Finnie, University of Adelaide, Australia.
and Professor Catriona A. McLean from the University of Melbourne, Australia for their assistance. We finally wish to acknowledge two anonymous reviewers for the careful reading of the manuscript and their helpful suggestions to improve the quality of this work.

**Author Contributions**

E.J.H., B.J.M., S.F.J. and G.B. designed and planned the experimental work. E.J.H., L.S. and F.C.B. performed the research. E.J.H., S.M.J., D.J.C. B.J.M., S.F.J. and G.B. interpreted and analyzed the data. E.J.H., L.S. and G.B. performed the statistical analysis. E.J.H., L.S. and G.B. wrote the manuscript. All authors reviewed the manuscript.

**Additional Information**

**Supplementary information** accompanies this paper at [https://doi.org/10.1038/s41598-019-42782-x](https://doi.org/10.1038/s41598-019-42782-x).

**Competing Interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2019